CA2223469A1 - Use of dopamine receptor antagonists in palliative tumour therapy - Google Patents

Use of dopamine receptor antagonists in palliative tumour therapy

Info

Publication number
CA2223469A1
CA2223469A1 CA002223469A CA2223469A CA2223469A1 CA 2223469 A1 CA2223469 A1 CA 2223469A1 CA 002223469 A CA002223469 A CA 002223469A CA 2223469 A CA2223469 A CA 2223469A CA 2223469 A1 CA2223469 A1 CA 2223469A1
Authority
CA
Canada
Prior art keywords
palliative
receptor antagonists
dopamine receptor
tumour therapy
alkylphosphocholines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002223469A
Other languages
French (fr)
Other versions
CA2223469C (en
Inventor
Bernd Nickel
Peter Hilgard
Thomas Klenner
Jurgen Engel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2223469A1 publication Critical patent/CA2223469A1/en
Application granted granted Critical
Publication of CA2223469C publication Critical patent/CA2223469C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The side effect of decrease in body weight caused by the alkylphosphocholines such as miltefosine can be antagonized by certain antagonists such as domperidone and pimozide. It is important here that the combination of alkylphosphocholine plus antidote does not have any effect on the antitumour action of the alkylphosphocholines. The combination also caused no new side effects in the animals.
CA002223469A 1996-12-06 1997-12-04 Use of dopamine receptor antagonists in palliative tumour therapy Expired - Fee Related CA2223469C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19650778.2 1996-12-06
DE19650778A DE19650778C2 (en) 1996-12-06 1996-12-06 Use of dopamine receptor antagonists in palliative tumor therapy

Publications (2)

Publication Number Publication Date
CA2223469A1 true CA2223469A1 (en) 1998-06-06
CA2223469C CA2223469C (en) 2005-08-23

Family

ID=7813911

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002223469A Expired - Fee Related CA2223469C (en) 1996-12-06 1997-12-04 Use of dopamine receptor antagonists in palliative tumour therapy

Country Status (11)

Country Link
US (3) US6093704A (en)
EP (1) EP0858807B1 (en)
JP (1) JPH10167969A (en)
AT (1) ATE192044T1 (en)
BR (1) BR9706229A (en)
CA (1) CA2223469C (en)
DE (2) DE19650778C2 (en)
DK (1) DK0858807T3 (en)
ES (1) ES2146063T3 (en)
GR (1) GR3033768T3 (en)
PT (1) PT858807E (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383605B2 (en) * 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
JP2005535688A (en) * 2002-07-30 2005-11-24 ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of alkylphosphocholines in combination with antitumor drugs
AU2006328479B2 (en) 2005-12-19 2012-03-08 Aeterna Zentaris Gmbh Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
WO2009148623A2 (en) * 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
WO2011123691A1 (en) 2010-03-31 2011-10-06 Keryx Biopharmaceuticals, Inc. Perifosine and capecitabine as a combined treatment for cancer
KR102500766B1 (en) 2017-12-29 2023-02-17 삼성전자주식회사 Apparatus for measuring biological signal and operating method thereof
KR102203334B1 (en) * 2019-04-12 2021-01-15 성균관대학교산학협력단 Combination therapy of anticancer drugs and pimozide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707484A (en) * 1986-11-25 1987-11-17 Hoffmann-La Roche Inc. Substituted piperidinomethylindolone and cyclopent(b)indolone derivatives
JPS6483016A (en) * 1987-09-25 1989-03-28 Arakawa Chem Ind Regulator for motile function of gastrointestinal tract
ATE201021T1 (en) * 1995-07-28 2001-05-15 Dainippon Pharmaceutical Co (R)-5-BROMO-N-(1-ETHYL-4-METHYLHEXAHYDRO-1H-1,4DIAZEPINE-6-YL)-2-METHOXY-6-METHYLAMINO-3-PYRIDINE CARBOXAMIDE, METHOD FOR THE PRODUCTION THEREOF AND MEDICAL MEDICINE CONTAINING THE SAME PREPARATION

Also Published As

Publication number Publication date
GR3033768T3 (en) 2000-10-31
JPH10167969A (en) 1998-06-23
US6696428B2 (en) 2004-02-24
CA2223469C (en) 2005-08-23
DE59701508D1 (en) 2000-05-31
ES2146063T3 (en) 2000-07-16
EP0858807A3 (en) 1999-03-24
PT858807E (en) 2000-09-29
DE19650778A1 (en) 1998-06-10
EP0858807A2 (en) 1998-08-19
US6576624B1 (en) 2003-06-10
US6093704A (en) 2000-07-25
EP0858807B1 (en) 2000-04-26
ATE192044T1 (en) 2000-05-15
DE19650778C2 (en) 2001-01-04
US20030008846A1 (en) 2003-01-09
BR9706229A (en) 1999-05-04
DK0858807T3 (en) 2000-07-31

Similar Documents

Publication Publication Date Title
FR13C0062I1 (en)
PA8481501A1 (en) 4-CARBOXYAMINO-2-METHYL-1,2,3,4-TETRAHYDROKINOLINS
IL142921A0 (en) USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
GB2277873B (en) Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
GR3022997T3 (en) Synergistic therapeutic compositions and methods
HUP0300382A3 (en) 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds
EP0764030A4 (en) Use of autoantibodies for tumor therapy and prophylaxis
GR3022060T3 (en) Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication
GEP20033092B (en) Purine Inhibitors of Cyclin Dependent Kinase 2 and Ik-Aa
GR3035971T3 (en) Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents.
MY110217A (en) Use of l-deprenyl for retarding deterioration due to aging in dogs
HK26294A (en) Stabilization of the preservative thiomersal in ophthalmic pharmaceutical compositions
PL356100A1 (en) Lipoxin a4
CA2223469A1 (en) Use of dopamine receptor antagonists in palliative tumour therapy
IL132853A0 (en) Combination therapy for modulating the human sexual response
SI1272177T1 (en) Method and formulation for treating resistance to antihypertensives and related conditions
HU912186D0 (en) The use of gm-monosialogangliosides and their internal esthers for preventing getting accustomed to the analgetic effect of morphin and its analogues in human beings
PT971710E (en) USE OF QUELERITRINA AND RADIACAO FOR TUMOR THERAPY
HK1047549A1 (en) Il6ril6 chimera for the treatment of neurodegeneraive diseases.
ZA943342B (en) The use of compositions for combating tumour diseases
IL114655A (en) USE OF GnRH ANTAGONIST IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF A GONADAL-STEROID DEPENDENT CONDITION IN A MAMMAL
IL89910A0 (en) Tp-receptor antagonists and compositions for modifying the action of myofibroblasts
ZA893261B (en) Synergistic combinations and their use as therapeutic agents
MXPA02004704A (en) Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders.
ZA901364B (en) Agent for combatting the effects of low electrolyte levels in performing animals

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20131204